Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis

Medical Science Monitor

Volumn 18, Issue 8, 2012, Pages

  Grzegorzewska, Alicja E ^a   Frankiewicz, Dorota ^b   Breborowicz, Danuta ^a   Matławska, Irena ^a   Bylka, Wiesława ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Voivodship Specialty Hospital   (Poland)

Author keywords

Kaposi sarcoma; Rheumatoid arthritis; Tryptolide

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; KETOPROFEN; METHOTREXATE; PACLITAXEL; RHEUMATOID FACTOR; SINDAXEL; SODIUM AUROTHIOSULFATE; TRIPTOLIDE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLISTER; CASE REPORT; DOPPLER ECHOGRAPHY; DRUG WITHDRAWAL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOPHENOTYPING; KAPOSI SARCOMA; LABORATORY TEST; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEG EDEMA; LIQUID CHROMATOGRAPHY; PETECHIA; POWDER; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DEFECT; TREATMENT DURATION; ULCER; VALVULAR HEART DISEASE; VASCULITIS;

EID: 84866085025     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.883256     Document Type: Article

References (35)

1. Kupchan SM, Court WA, Dailey RG Jr et al: Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc, 1972; 94: 7194-95
2. Liu CF, Lin N: [Progress in research on mechanisms of anti-rheumatoid arthritis of triptolide]. Zhongguo Zhong Yao Za Zhi, 2006; 31: 1575-79 [in Chinese]
3. Su D, Song Y, Li R: [Comparative clinical study of rheumatoid arthritis treated by triptolide and an ethyl acetate extract of Tripterygium wilfordii]. Zhong Xi Yi Jie He Za Zhi, 1990; 10: 144-46, 131 [in Chinese]
4. Tao X, Cush JJ, Garret M, Lipsky PE: A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J Rheumatol, 2001; 28: 2160-67
5. Dudderidge TJ, Khalifa M, Jeffery R et al: Donor-derived human herpes virus 8-related Kaposi's sarcoma in renal allograft ureter. Transpl Infect Dis, 2008; 10: 221-26
6. Kitzen JJ, de Jonge MJ, Lamers CH et al: Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer, 2009; 45: 1764-72
7. Wang Z, Jin H, Li C, Hou Y et al: Heat shock protein 72 protects kidney proximal tubule cells from injury induced by triptolide by means of activation of the MEK/ERK pathway. Int J Toxicol, 2009; 28: 177-89
8. Liu L, Jiang Z, Liu J et al: Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Toxicology, 2010; 271: 57-63
9. Tao XL, Sun Y, Dong Y et al: A prospective, controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin Med J (Engl), 1989; 102: 327-32
10. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA, 1949; 140: 659-62
11. Osawa R, Kato N, Yanagi T, Yamane N: Clearance of recurrent, classical Kaposi's sarcoma using multiple paclitaxel treatments. Acta Derm Venereol, 2007; 87: 435-36
12. Lee SY, Jo YM, Chung WT et al: Disseminated cutaneous and visceral Kaposi sarcoma in a woman with rheumatoid arthritis receiving leflunomide. Rheumatol Int, 2012; 32(4): 1065-68
13. Ou Yang XK, Jin MC, He CH: Simultaneous determination of triptolide and tripdiolide in extract of Tripterygium wilfordii Hook. f. by LC-APCIMS. Chromatogr, 2007; 65: 373-75
14. Matta R, Wang X, Ge H et al: Triptolide induces anti-inflammatory cellular responses. Am J Transl Res, 2009; 1: 267-82
15. Luo Y, Shi C, Liao M: [Advance in the anti-tumor mechanism of triptolide]. Zhongguo Zhong Yao Za Zhi, 2009; 34: 2024-26 [in Chinese]
16. Benucci M, Maniscalchi F, Manfredi M: [Secondary amyloidosis complicated rheumatoid arthritis, prevalence study in Italian population]. Recenti Prog Med, 2007; 98: 16-19 [in Italian]
17. Cui D, Hoshii Y, Kawano H et al: Experimental AA amyloidosis in mice is inhibited by treatment with triptolide, a purified traditional Chinese medicine. Int Immunopharmacol, 2007; 7: 1232-40
18. Lindqvist E, Saxne T, Geborek P, Eberhardt K: Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis, 2002; 61: 1055-59
19. Penn I: Kaposi's sarcoma in immunosupressed patients. J Clin Lab Immunol, 1983; 12: 1-10
20. Louthrenoo W, Kasitanon N, Mahanuphab P et al: Kaposi's sarcoma in rheumatic diseases. Semin Arthritis Rheum, 2003; 32: 326-33
21. Antman K, Chang Y: Kaposi's sarcoma. N Engl J Med, 2000; 342: 1027-38
22. Mesri EA, Cesarman E, Boshoff C: Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer, 2010; 10: 707-19
23. Kim TG, Lee KH, Oh SH: Skin disorders in Korean patients infected with human immunodeficiency virus and their association with a CD4 lymphocyte count: a preliminary study. J Eur Acad Dermatol Venereol, 2010; 24: 1476-80
24. Gantt S, Kakuru A, Wald A et al: Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer, 2010; 54: 670-74
25. Clifford GM, Franceschi S: Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol, 2009; 5: 669-78
26. Ozen O, Bilezikçi B, Celasun B, Demirhan B: Ki-67 proliferation index in Kaposi's sarcoma after renal transplantation: findings in skin-only cases versus cases with internal-organ involvement. Transplant Proc, 2005; 37: 2190-94
27. De Thier F, Simonart T, Hermans P et al: Early-and late-stage Kaposi's sarcoma lesions exhibit similar proliferation fraction. Am J Dermatopathol, 1999; 21: 25-27
28. Sun S, Wang Y, Zhou Y: [Research progress on immunosuppressive activity of monomers extracted from Chinese medicine]. Zhongguo Zhong Yao Za Zhi, 2010; 35: 393-96 [in Chinese]
29. Wang XH, Zhang ZY: [Effect of tripterygium polyglucoside on T-lymphocyte subsets and serum interleukin-5 level in asthma patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2001; 21: 25-27 [in Chinese]
30. Tong X, Zheng S, Jin J et al: Triptolide inhibits cyclooxygenase-2 and inducible nitric oxide synthase expression in human colon cancer and leukemia cells. Acta Biochim Biophys Sin (Shanghai), 2007; 39: 89-95
31. Masood R, Cai J, Zheng T et al: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA, 1997; 94: 979-84
32. Akula SM, Ford PW, Whitman AG et al: B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood, 2005; 105: 4516-22
33. Ma T, Jham BC, Hu J et al: Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci USA, 2010; 107: 14363-68
34. Hu KB, Liu ZH, Liu D, Li LS: Inhibition of vascular endothelial growth factor expression and production by triptolide. Planta Med, 2002; 68: 368-69
35. He MF, Huang YH, Wu LW et al: Triptolide functions as a potent angiogenesis inhibitor. Int J Cancer, 2010; 126: 266-78